Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium BX520
- Development stage
- Preclinical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium BX520 is a specific strain of *Bifidobacterium* that produces high levels of indole metabolites. It is being investigated for its potential to prevent brain inflammation in necrotizing enterocolitis (NEC), a severe gastrointestinal disease in premature infants. The mechanism of action involves modulating the indoleamine 2,3-dioxygenase 1 (IDO1)-kynurenine axis through targeted intervention in the gut microbiota. Specifically, it activates the ileal aryl hydrocarbon receptor (AHR), which improves the intestinal barrier by increasing the expression of tight junction proteins like ZO1 and Occludin. Furthermore, Bifidobacterium BX520 inhibits IDO1 protein levels in the hippocampus, thereby ameliorating brain inflammatory responses characterized by reduced levels of IL-1β and NF-κB.
02
Targets
IDO1 (Indoleamine 2,3-dioxygenase 1)AHR (Aryl hydrocarbon receptor)
Beyond the preview
Go deeper on Bifidobacterium BX520.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium BX520.